{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:55:44Z","timestamp":1740135344587,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Membranoproliferative glomerulonephritis (MPGN), a rare glomerulonephritis that causes nephrotic syndrome in children, is often difficult to treat. Typical immunofluorescence findings include strong C3 staining in a granular pattern along the glomerular capillary wall and negative IgA staining. IgA-dominant MPGN without hypocomplementemia has been reported. Herein, we report a rare case of MPGN with hypocomplementemia and predominant IgA subclass 2 deposits.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>An 11-year-old girl showed proteinuria on a school urinalysis screening and presented with upper eyelid edema. The urinalysis showed elevated urinary protein levels and hematuria. Laboratory examinations revealed the following: serum albumin, 1.3\u00a0g\/dL; serum creatinine, 0.54\u00a0mg\/dL; and C3c, 67\u00a0mg\/dL (normal range: 73\u2013138\u00a0mg\/dL). The physical and laboratory findings did not suggest autoimmune diseases. A renal biopsy was then performed. Specimen examination under a light microscope showed mesangial cell proliferation, increased mesangial matrix with lobulation, and some double contours of the glomerular basement membrane in almost all glomeruli, which are characteristic findings of MPGN. Immunofluorescent studies showed IgA deposits not only in the mesangial regions but also along the capillary walls, which were more strongly stained than C3. IgA subclass staining showed a stronger immunoreactivity for IgA2 than IgA1. Electron microscopic studies showed electron-dense deposits in the subendothelial, subepithelial, and paramesangial regions. Based on these findings, the patient was diagnosed with IgA-dominant MPGN. Accordingly, she was treated with three courses of methylprednisolone pulse therapy (MPT), followed by prednisolone, mizoribine, and lisinopril. Although hypocomplementemia improved after three courses of MPT, nephrotic-range proteinuria and hypoalbuminemia remained; therefore, two courses of MPT were additionally administered, and the immunosuppressant was changed from mizoribine to cyclosporine (CsA). Finally, the urinary protein level decreased, and a subsequent renal biopsy, two years later, showed improvement in the lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We report an atypical case of MPGN with IgA2 dominant deposits along the glomerular capillary wall and in the mesangial region. The case was refractory to standard therapy but sensitive to CsA, which resulted in remission. Our findings suggest that CsA may be useful as an immunosuppressant to treat refractory MPGN.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-022-02983-5","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T12:30:34Z","timestamp":1667824234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cyclosporine therapy could be considered for membranoproliferative glomerulonephritis with immunoglobulin A deposits: a case report"],"prefix":"10.1186","volume":"23","author":[{"given":"Yuko","family":"Hidaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-217X","authenticated-orcid":false,"given":"Hiroshi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keishiro","family":"Furuie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Kuraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"2983_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000167049","volume":"6","author":"SP Andreoli","year":"1986","unstructured":"Andreoli SP, Yum MN, Bergstein JM. IgA nephropathy in children: significance of glomerular basement membrane deposition of IgA. Am J Nephrol. 1986;6:28\u201333.","journal-title":"Am J Nephrol"},{"key":"2983_CR2","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2215\/CJN.05650516","volume":"12","author":"K Koike","year":"2017","unstructured":"Koike K, Ikezumi Y, Tsuboi N, Kanzaki G, Haruhara K, Okabayashi Y, et al. Glomerular Density and Volume in Renal Biopsy Specimens of Children with Proteinuria Relative to Preterm Birth and Gestational Age. Clin J Am Soc Nephrol. 2017;12:585\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2983_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10157-004-0330-y","volume":"9","author":"K Iitaka","year":"2005","unstructured":"Iitaka K, Nakamura S, Moriya S, Koshino H, Iwanami N, Sakai T, et al. Hypocomplementemia and membranoproliferative glomeruloneophritis in children. Clin Exp Nephrol. 2005;9:31\u20133.","journal-title":"Clin Exp Nephrol"},{"key":"2983_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1620\/tjem.228.253","volume":"228","author":"A Kurosu","year":"2012","unstructured":"Kurosu A, Oka N, Hamaguchi T, Yoshikawa N, Joh K. Infantile immunoglobulin A nephropathy showing features of membranoproliferative glomerulonephritis. Tohoku J Exp Med. 2012;228:253\u20138.","journal-title":"Tohoku J Exp Med"},{"key":"2983_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.humpath.2018.06.031","volume":"81","author":"NK Andeen","year":"2018","unstructured":"Andeen NK, Jefferson JA, Akilesh S, Alpers CE, Bissonnette ML, Finn LS, et al. IgA-dominant glomerulonephritis with a membranoproliferative pattern of injury. Hum Pathol. 2018;81:272\u201380.","journal-title":"Hum Pathol"},{"key":"2983_CR6","first-page":"168","volume":"60","author":"SN Emancipator","year":"1989","unstructured":"Emancipator SN, Lamm ME. IgA nephropathy: pathogenesis of the most common form of glomerulonephritis. Lab Invest. 1989;60:168\u201383.","journal-title":"Lab Invest"},{"key":"2983_CR7","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1053\/ajkd.2001.28611","volume":"38","author":"S Hisano","year":"2001","unstructured":"Hisano S, Matsushita M, Fujita T, Endo Y, Takebayashi S. Mesangial IgA2 deposits and lectin pathway-mediated complement activation in IgA glomerulonephritis. Am J Kidney Dis. 2001;38:1082\u20138.","journal-title":"Am J Kidney Dis"},{"key":"2983_CR8","first-page":"206","volume":"53","author":"S Karashima","year":"2000","unstructured":"Karashima S, Hattori S, Nakazato H, Awata H, Seguchi S, Ikeda S, et al. Membranoproliferative glomerulonephritis in congenital portosystemic shunt without liver cirrhosis. Clin Nephrol. 2000;53:206\u201311.","journal-title":"Clin Nephrol"},{"key":"2983_CR9","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1007\/s00467-005-2037-z","volume":"20","author":"K Kano","year":"2005","unstructured":"Kano K, Nishikura K, Arisaka O. Does growth hormone therapy induce IgA nephropathy? Pediatr Nephrol. 2005;20:1821\u20132.","journal-title":"Pediatr Nephrol"},{"key":"2983_CR10","first-page":"165","volume":"6","author":"M Endo","year":"1997","unstructured":"Endo M, Okuhara K. A girl with growth hormone deficiency with IgA nephropathy and insulin dependent diabetes mellitus. (abstract). Clin Pediatr Endocrinol. 1997;6:165.","journal-title":"Clin Pediatr Endocrinol"},{"key":"2983_CR11","first-page":"128","volume":"6","author":"H Sasaki","year":"1997","unstructured":"Sasaki H, Takeda N, Nishida Y, Kawamura I, Tanaka M. IgA nephropathy in a boy with recombinant human growth hormone. (abstract). Clin Pediatr Endocrinol. 1997;6:128.","journal-title":"Clin Pediatr Endocrinol"},{"key":"2983_CR12","first-page":"17","volume":"8","author":"H Sasaki","year":"2001","unstructured":"Sasaki H, Takeda N, Nishida Y, Fujiwara T. Growth hormone and kidney: clinical study of growth hormone therapy in childhood. (in Japanese). The Reports of the Kurashiki Nephrology. Forum. 2001;8:17\u201322.","journal-title":"Forum"},{"key":"2983_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0002-9343(83)90606-X","volume":"74","author":"JS Cameron","year":"1983","unstructured":"Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med. 1983;74:175\u201392.","journal-title":"Am J Med"},{"key":"2983_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/00005792-198511000-00005","volume":"64","author":"PT McEnery","year":"1985","unstructured":"McEnery PT, McAdams AJ, West CD. The effect of prednisone in a high-dose, alternate-day regimen on the natural history of idiopathic membranoproliferative glomerulonephritis. Med (Baltim). 1985;64:401\u201324.","journal-title":"Med (Baltim)"},{"key":"2983_CR15","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/S0022-3476(05)82712-X","volume":"116","author":"PT McEnery","year":"1990","unstructured":"McEnery PT. Membranoproliferative glomerulonephritis: the Cincinnati experience\u2013cumulative renal survival from 1957 to 1989. J Pediatr. 1990;116:S109\u201314.","journal-title":"J Pediatr"},{"key":"2983_CR16","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S0272-6386(99)70007-7","volume":"34","author":"MC Braun","year":"1999","unstructured":"Braun MC, West CD, Strife CF. Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Am J Kidney Dis. 1999;34:1022\u201332.","journal-title":"Am J Kidney Dis"},{"key":"2983_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF00866289","volume":"6","author":"P Tarshish","year":"1992","unstructured":"Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone\u2013a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992;6:123\u201330.","journal-title":"Pediatr Nephrol"},{"key":"2983_CR18","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00467-009-1322-7","volume":"25","author":"B Alchi","year":"2010","unstructured":"Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol. 2010;25:1409\u201318.","journal-title":"Pediatr Nephrol"},{"key":"2983_CR19","first-page":"26","volume":"11","author":"N Bagheri","year":"2008","unstructured":"Bagheri N, Nemati E, Rahbar K, Nobakht A, Einollahi B, Taheri S. Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med. 2008;11:26\u20139.","journal-title":"Arch Iran Med"},{"key":"2983_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1159\/000064298","volume":"91","author":"T Kiyomasu","year":"2002","unstructured":"Kiyomasu T, Shibata M, Kurosu H, Shiraishi K, Hashimoto H, Hayashidera T, et al. Cyclosporin A treatment for membranoproliferative glomerulonephritis type II. Nephron. 2002;91:509\u201311.","journal-title":"Nephron"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02983-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-022-02983-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-022-02983-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T12:31:37Z","timestamp":1667824297000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-022-02983-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2983"],"URL":"https:\/\/doi.org\/10.1186\/s12882-022-02983-5","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the Institutional Committee and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards (64th WMA General Assembly, Fortaleza, Brazil, October 2013).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient and her parents provided written informed consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"358"}}